Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc. is a U.S.-based clinical-stage pharmaceutical company focused on developing dermatology products, including XYNGARI™ and DMT410, with a recent shift toward OTC acne kits and other skin-condition applications. The company has no approved products or product revenue to date and is still building the regulatory, manufacturing, and commercial infrastructure needed to launch products.

— Dermata Therapeutics, Inc.
%
Prescription and clinical-stage dermatology candidates60% Includes XYNGARI™ and related clinical programs being developed for acne and other skin conditions.
OTC acne products25% Includes planned over-the-counter acne kits intended for consumer retail and digital channels.
Botulinum toxin and aesthetic skin programs10% Includes DMT410 and related applications for aesthetic and medical dermatology uses.
Platform and collaboration activities5% Includes technology platform development, clinical collaborations, and licensing-related work.

Dermata’s direct customers are not yet commercial end users, because the company has no approved products and no...

  • OTC acne consumersprimary

    Consumers who would buy OTC acne kits for convenient self-treatment through retail or digital channels.

  • Dermatology clinics and professionalssecondary

    Clinics and practitioners that may use or recommend topical dermatology products in professional settings.

  • Retail and e-commerce channel partnersprimary

    Distributors, retailers, and online channels that would carry and market the company’s OTC products.

  • Clinical trial participantssecondary

    Patients enrolled in studies for acne, hyperhidrosis, and other skin-condition programs.

  • Strategic collaboratorssecondary

    Partners such as Revance that support clinical development, validation, or future commercialization.

Dermata is headquartered in the United States and its disclosed clinical activity is concentrated there, including a...

  • •Headquartered in the United States
  • •Clinical trial sites disclosed in the U.S.
  • •Commercial plans currently centered on U.S. OTC pathways
  • •Supply chain and distribution may involve third-party vendors
  • •International competition and trade policy can affect costs

Dermata is pivoting from an Rx development model toward OTC pathways, with a focus on acne kits and related dermatology...

01
OTC acne commercializationshort-term

OTC pathways may reduce regulatory complexity and manufacturing cost versus Rx development.

02
Capital preservation and financingshort-term

The company has recurring losses and a going-concern risk, so funding is required to continue operations.

03
Clinical and regulatory executionmedium-term

Successful trials and regulatory pathway selection are needed to support product launch and value creation.

04
Manufacturing and supply-chain buildoutmedium-term

Commercialization depends on compliant manufacturing and reliable third-party supply chains.

Dermata is a pre-revenue biotech with substantial financing risk, regulatory execution risk, and dependence on...

critical

Insufficient financing and going-concern risk

The company has recurring losses, limited cash runway, and needs more capital to fund development and launch plans.

Scope
Operations, R&D, and commercialization
Materiality
high
high

OTC regulatory pathway uncertainty

Moving from Rx to OTC monograph or OTC NDA pathways can require reformulation, relabeling, or additional studies.

Scope
Product launch timing and cost
Materiality
high
high

Third-party manufacturing and supply-chain dependence

The company relies on external manufacturers and logistics providers for clinical and commercial supply.

Scope
Product availability and margins
Materiality
high
medium

Counterfeit and unauthorized products

OTC products can be copied or sold through unauthorized channels, harming consumers and brand trust.

Scope
Brand reputation and sales
Materiality
medium
medium

Competition from private label and established brands

OTC dermatology products compete against heavily marketed brands and lower-priced retailer labels.

Scope
Market share and pricing
Materiality
medium
Research and development expense estimation
Can materially change quarterly operating loss
Prepaid external development costs
Creates quarter-to-quarter volatility in R&D
Stock-based compensation
Affects reported losses and dilution analysis
Going-concern assessment
Signals financing dependence and survival risk

Turn Therapeutics Inc.

TTRX · Pharmaceutical Preparations

CAPRICOR THERAPEUTICS, INC.

CAPR · Pharmaceutical Preparations

STRATA Skin Sciences, Inc.

SSKN · Surgical & Medical Instruments & Apparatus

Journey Medical Corp

DERM · Pharmaceutical Preparations

ABEONA THERAPEUTICS INC.

ABEO · Pharmaceutical Preparations

Adapti, Inc.

ADTI · Services-Amusement & Recreation Services

: 28.4.2026